Related Experiment Video
Updated: Jan 13, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel
Dhruv Ahuja1,2, Kuan-Hung Yeh3, Sagar B Patel1
1Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
Abstract:
We conducted a USA claims-based cohort study in 20,705 patients with inflammatory bowel diseases (IBD) on advanced therapies to estimate the overall and comparative risk of tuberculosis between advanced therapies using inverse probability of treatment weighted Cox proportional hazards model. The incidence rate (IR, per 100,000 person-years) of tuberculosis with TNF antagonists (n = 9378) and non-TNF-targeting biologics (anti-integrins [n = 5877], anti-interleukins [n = 5450]) was similar (38 [95% CI, 8-69] vs. 33[7-59]). Adjusting for covariates, risk of tuberculosis was similar (HR, 1.16 [0.41-3.31]). In low incidence regions like USA, the incidence of tuberculosis after starting advanced therapies for IBD is very low, and comparable across advanced therapies.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

